Investment Q&A

Q: Hello Team,

SDGR, buy, sell, or hold?

I would appreciate if you could speak to, cash flow, debt, and growth expectations.

Thanks,
Saeed

Q: Hi , Peter & Team:

I'm in the process of selling some of the losers to offset the capital gain. Which of the above Co. may not rebound as well, that is the most likely to sell now, to the ones least likely to sell ( worth holding).
Take as many credit as you see fit. Thank you for all the great service and advice you have given through the year.

Q: Hello team,

I have to crystalize some losses to offset gains. I have a substantial position in ABCL (-56%) and BHC (-78%) and can sell either completely and be done with offsetting the gains. Do you suggest I do that or should I get rid of SDGR (-23%), BMBL (-38%) and PENN (-23%) as well ,if ABCL is worth holding onto, at least partially?

I know other than BHC, they all do have a good bounce potential after the tax-loss season is over. However, I also know that something like BMBL or even ABCL may be broken stories and may take a very long time to recover.

I appreciate it if you can share in which order you would sell and why (if you could kindly include the main reason for each).

Best!

Q: May you provide an update on this security?
I am down 40%, would you be inclined to hold or crystallize a loss?
Thank you

Q: Hello team,

Which one would you add to at this point, and why? They are both very tiny positions but equally down from the time of purchase a year ago. I appreciate it if you can reflect on their financial situation right now, and say which one you expect to grow better. I am a moderate-to-high-risk-buy-and-hold investor. So, I love growthy stocks.

Thank you for your impeccable support.

Q: Can you provide your outlook for this company? I noticed that Bill Gate's Foundation recently acquired shares.

Q: Hi Peter
Schrodinger
I’d like your input on this company . Is it a buy ? Is it the type of company that 5i recommend .
Give me all the details

Q: I have decided to exit all large cap stocks and move down the market cap range.
Please list your 5 most compelling US small caps for an agressive investor, irrespective of sector.
These would be to complement my current small cap holdings. If you feel any of the below holdings can be added to, please advise.
CELH
GAN
ICAD
ICHR
MGNI
MED
MITK
RDFN
SDGR

Thank you for your excellent service. I have made a small fortune with 5i

Q: Good afternoon, 3 questions...
Could you please give me your thoughts (after one public quarter) on Jfrog for a long term hold for growth?

There are lots of great new companies out there and only 1 public quarter for them. How would you rank the top ten “tech” stocks that had a IPO in 2020?

Your new USA fund forgive me if this is elsewhere but does this affect your answers or ability to answer any USA stock questions or does it not impact the current/past services? As I find your USA recommendations to be extremely valuable as a Canadian investor.

Thank you!

Q: A co-worker of mine has brought up this company to my attention last couple of days it looks like this company went public just this past FEBRUARY, i know that it is very new to the stock market do you have any inside information on this company. Thank you
again Wilson

Q: I just received an email from Citron talking about SDGR. They feel it is the second coming of TSLA but of course, in a different industry.
They are a brand new IPO and are up 20% today, but would this be worth purchasing in the event that it pulls back to prior to the letter and held for a period of time.
In a nutshell they recap it thusly:

"Through use of artificial intelligence and a world class scientific team that is unmatched by ANY public company, Schrodinger has created a software platform that integrates predictive physics-based methods with machine learning to become the leader in molecular simulation that 1) reduces the average time and cost required to identify a drug development candidate and 2) increases the probability of drug discovery programs entering clinical development.

With the global pharma industry spending approximately $180 billion on R&D annually, this innovative software platform is completely disrupting the drug development process."

Would you invest in this concept yourselves, once you research more about it.? I know its not a p/e , value play it may or may not be TSLA of 10 years ago.

Thanks

Sheldon